ABSTRACT
Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates (PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate- to-severe plaque psoriasis.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Etanercept/therapeutic use , Immunosuppressive Agents/therapeutic use , Psoriasis/drug therapy , Adolescent , Adult , Aged , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Injections, Subcutaneous , Male , Middle Aged , Patient Safety , Prospective Studies , Psoriasis/immunology , Psoriasis/physiopathology , Severity of Illness Index , Treatment OutcomeABSTRACT
Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis.Since most clinical trials examined etanercept in combination with other drugs,the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established.This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy.These patients were treated with etanercept at a subcutaneous dose of 25 mg,twice a week,for 12 weeks.All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores.At 4,8,and 12 weeks after treatment,the response rates (PASI75) were 0％,21.31％,and 40.98％,respectively.It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate-to-severe plaque psoriasis.
ABSTRACT
The irradiance in microscopic lithography using a digital micro-mirror device (DMD) as a virtual digital mask generator is influenced by diffraction effects that have been exploited to fabricate microstructures. Based on the established model, the theoretical analysis and simulation of DMD diffraction characteristics has been studied. A novel method without masking to fabricate a micro-lens by pixilation of micro-mirrors inside the DMDs used in microscopic lithography has been proposed. It is a method of precise control of photon-induced curing behavior of photoresist by full use of diffraction effects and verification of the feasibility of the fabrication method based on diffraction. The introduced method provides an option for accurate and flexible micro-fabrication of microstructures.
Subject(s)
Lenses , Photography/instrumentation , Refractometry/instrumentation , Signal Processing, Computer-Assisted/instrumentation , Computer-Aided Design , Equipment Design , Equipment Failure Analysis , MiniaturizationABSTRACT
The acquisition of metastasis potential is a critical point for malignant tumors. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24) is a potential tumor suppress gene and frequently down-regulated in malignant tumors. It has been implicated that overexpression of MDA-7 led to proliferation inhibition in many types of human tumor. Invasion is an important process which is potential to promote tumor metastasis. However, the role and potential molecular mechanism of mda-7/IL-24 to inhibit the invasion of human melanoma cancer is not fully clear. In this report, we identified a solid role for mda-7/IL-24 in invasion inhibition of human melanoma cancer LiBr cells, including decreasing of adhesion and invasion in vitro, blocking cell cycle, down-regulating the expression of ICAM-1, MMP-2/9, CDK1, the phosphorylation of ERK and Akt, NF-κB and AP-1 transcription activity. Meanwhile, there was an increased expression of PTEN in mda-7/IL-24 over-expression LiBr cells. Our results demonstrated that mda-7/IL-24 is a potential invasion suppress gene, which inhibits the invasion of LiBr cells by the down-regulation of ICAM-1, MMP-2/9, PTEN, and CDK1 expression. The molecular pathways involved were the MAPK/ERK, PI3K-Akt, NF-κB, and AP-1. These findings suggest that mda-7/IL-24 may be used as a possible therapeutic strategy for human melanoma cancer.
Subject(s)
Interleukins/metabolism , CDC2 Protein Kinase/genetics , CDC2 Protein Kinase/metabolism , Cell Line, Tumor , Cell Movement , Down-Regulation , G2 Phase Cell Cycle Checkpoints , Humans , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Interleukins/genetics , M Phase Cell Cycle Checkpoints , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Melanoma/metabolism , Melanoma/pathology , NF-kappa B/genetics , NF-kappa B/metabolism , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/metabolism , Phosphorylation , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Transcription Factor AP-1/genetics , Transcription Factor AP-1/metabolism , Up-RegulationABSTRACT
OBJECTIVE: To establish a RP-HPLC method for fast and simultaneous determination of four index contents, which are Genpioside, Baicalin, Berberine Hydrochloride and Ammonium Glyeyrrhizinate, in Qingwei Huanglian tablets. METHOD: A separation was well achieved by gradient elution on a Hypersil C18 (4.6 mm x 250 mm, 5 microm) column with the mobile phases of acetontrile -0.5% triethylamine water-solution (pH 3.0) at a flow rate of 1.0 mL x min(-1), detection wavelength of 230 nm, and room temperature. RESULT: The calibration curve were linear in the ranges of 4.82-77.2, 5.80-92.8, 1.63-26.1 and 6.40-102 microg x mL(-1) (r = 0.9997-0.9999) for genpioside, baicalin, berberine hydrochloride and ammonium glyeyrrhizinate, respectively. The average recoveries of four index components were not less than 98.0%. CONCLUSION: The method is convenient, rapid and accurate. It is suitable for the quality control of Qingwei Huanglian tablets.
